



MultiNano@MBM: Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immune-therapies

Coordinator: Ronit Satchi-Fainaro, Tel Aviv University, Tel-Aviv, Israel,
ronitsf@tauex.tau.ac.il

Partners: Helena F Florindo, Universidade de Lisboa, Lisbon, Portugal | Steffen Jung,
Weizmann Institute of Science, Rehovot, Israel | Juan A. Récio, Vall d'Hebron University
Hospital Institute of Research/Oncology, Barcelona, Spain.



“evaluate the ability
of a novel biological
dual-targeted
nanomedicine.”

Melanoma is the most lethal skin cancer. Two thirds of melanoma patients present brain metastasis that has very low response rates to current systemic therapies. MultiNano@MBM proposes an established immune-competent mouse model of melanoma brain metastasis (MBM) to evaluate the ability of a novel biological dual-targeted nanomedicine to overcome tumor immune suppression and modulate both PD-L1 immune-checkpoint and mitogen-activated protein kinase (MAPK) signaling pathways, inhibiting tumor cell proliferation and enhancing tumor apoptosis.

